Uploaded March 2026 | Updated September 2026, 2 weeks ago
JAMA Article: jamanetwork.com/journals/jamaoncology/article-abstract/2841671
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
0:45 What is the optimal duration for a course of hormone therapy?
5:51 How does this article determine intermediate risk?
6:52 Does a lesion on one side of the prostate vs. a lesion on both make a difference?
7:54 Is the standard 18-24 month course of therapy not actually optimal?
10:48 What makes hormone therapy worth the side effects that sometimes accompany it?
12:43 Is the higher risk of mortality associated with extended therapy a product of weight gain?
13:03 What if my doctor doesn't agree with my course of treatment?
17:01 Does this data have any effect on Gleason 9 and 10s?
17:57 Alex's Conclusions
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
JAMA Article: jamanetwork.com/journals/jamaoncology/article-abstract/2841671
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
0:45 What is the optimal duration for a course of hormone therapy?
5:51 How does this article determine intermediate risk?
6:52 Does a lesion on one side of the prostate vs. a lesion on both make a difference?
7:54 Is the standard 18-24 month course of therapy not actually optimal?
10:48 What makes hormone therapy worth the side effects that sometimes accompany it?
12:43 Is the higher risk of mortality associated with extended therapy a product of weight gain?
13:03 What if my doctor doesn't agree with my course of treatment?
17:01 Does this data have any effect on Gleason 9 and 10s?
17:57 Alex's Conclusions
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
